Revenue guidance for 2026 is revised to €2.1–2.16 billion and EBITDA to €88–92 million, mainly due to price pressure in pharmaceutical supply and regulatory changes impacting cannabis margins. Operational excellence initiatives, including site closures and cost optimization, are expected to improve…
Revenue guidance for 2026 has been raised, while EBITDA pre guidance is reduced due to price pressure and regulatory changes affecting high-margin products and medical cannabis. Operational efficiency measures are underway, with further details to be shared in upcoming reports.Original document: Me…
Medios AG/ Key word(s): Change in ForecastMedios AG: Earnings guidance for the financial year 2026 reduced – revenue guidance raised at the same time28.07.2026 / 19:49 CET/CESTThe issuer is solely responsible for the content of this announcement.Medios AG: Earnings guidance for the financial year 2…
Medios AG / Key word(s): Forecast / Full yearMedios AG: Adjusted guidance for the financial year 202628-Jul-2026 / 19:40 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.The issuer is solely respo…
